Tolvaptan
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317142

CAS#: 150683-30-0

Description: Tolvaptan is a selective, competitive vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan was approved by the U.S. Food and Drug Administration (FDA) on May 19, 2009.


Chemical Structure

img
Tolvaptan
CAS# 150683-30-0

Theoretical Analysis

MedKoo Cat#: 317142
Name: Tolvaptan
CAS#: 150683-30-0
Chemical Formula: C26H25ClN2O3
Exact Mass: 448.15537
Molecular Weight: 448.95
Elemental Analysis: C, 69.56; H, 5.61; Cl, 7.90; N, 6.24; O, 10.69

Price and Availability

Size Price Availability Quantity
10.0mg USD 90.0 2 Weeks
25.0mg USD 150.0 2 Weeks
50.0mg USD 250.0 2 Weeks
100.0mg USD 350.0 2 Weeks
200.0mg USD 450.0 2 Weeks
500.0mg USD 550.0 2 Weeks
1.0g USD 850.0 2 Weeks
2.0g USD 1450.0 2 Weeks
5.0g USD 2450.0 2 Weeks
10.0g USD 3450.0 2 Weeks
20.0g USD 4450.0 2 Weeks
50.0g USD 6950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: OPC-41061; OPC 41061; OPC41061; Tolvaptan; trade names Samsca; Jinarc; Resodim.

IUPAC/Chemical Name: N-(4-{[(5R)-7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-methylphenyl)-2-methylbenzamide

InChi Key: GYHCTFXIZSNGJT-XMMPIXPASA-N

InChi Code: InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)/t24-/m1/s1

SMILES Code: O=C(NC1=CC=C(C(N2CCC[C@@H](O)C3=CC(Cl)=CC=C32)=O)C(C)=C1)C4=CC=CC=C4C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 448.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sami SA, Moffett BS, Karlsten ML, Cabrera AG, Price JF, Dreyer WJ, Denfield SW, Jeewa A. Novel Use of Tolvaptan in a Pediatric Patient With Congestive Heart Failure Due to Duchenne Muscular Dystrophy and Congenital Adrenal Hyperplasia. J Pediatr Pharmacol Ther. 2015 Sep-Oct;20(5):393-6. doi: 10.5863/1551-6776-20.5.393. PubMed PMID: 26472954; PubMed Central PMCID: PMC4596126.

2: Vaduganathan M, Goldsmith SR, Senni M, Butler J, Gheorghiade M. Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. Eur J Heart Fail. 2015 Oct 7. doi: 10.1002/ejhf.415. [Epub ahead of print] PubMed PMID: 26443242.

3: De Las Peñas R, Ponce S, Henao F, Camps Herrero C, Carcereny E, Escobar Álvarez Y, Rodríguez CA, Virizuela JA, López López R. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan. Support Care Cancer. 2015 Oct 2. [Epub ahead of print] PubMed PMID: 26431960.

4: Ogawa H, Ajioka M, Ishii H, Okumura T, Murase Y, Osanai H, Nakasima Y, Asano H, Sakai K, Murohara T. Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure. Nagoya J Med Sci. 2015 Aug;77(3):355-62. PubMed PMID: 26412881; PubMed Central PMCID: PMC4574322.

5: Nishi H, Toda K, Miyagawa S, Yoshikawa Y, Fukushima S, Kawamura M, Yoshioka D, Saito T, Ueno T, Kuratani T, Sawa Y. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial. Surg Today. 2015 Sep 28. [Epub ahead of print] PubMed PMID: 26411431.

6: Blair HA, Keating GM. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs. 2015 Oct;75(15):1797-806. doi: 10.1007/s40265-015-0475-x. PubMed PMID: 26407729.

7: Olin JL, Mitchell G, Cremisi H. Experience with Tolvaptan for Euvolemic and Hypervolemic Hyponatremia in the Acute Care Setting. Hosp Pharm. 2015 May;50(5):380-5. doi: 10.1310/hpj5005-380. PubMed PMID: 26405324; PubMed Central PMCID: PMC4567204.

8: Tzoulis P, Waung JA, Bagkeris E, Carr H, Khoo B, Cohen M, Bouloux PM. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion. Clin Endocrinol (Oxf). 2015 Sep 19. doi: 10.1111/cen.12943. [Epub ahead of print] PubMed PMID: 26385871.

9: Felker GM, Mentz RJ, Adams KF, Cole RT, Egnaczyk GF, Patel CB, Fiuzat M, Gregory D, Wedge P, O'Connor CM, Udelson JE, Konstam MA. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. Circ Heart Fail. 2015 Sep;8(5):997-1005. doi: 10.1161/CIRCHEARTFAILURE.115.002259. PubMed PMID: 26374918.

10: Kimura M, Nawata K, Kinoshita O, Hatano M, Imamura T, Kinugawa K, Ono M. Successful Treatment of Intractable Fluid Retention Using Tolvaptan After Treatment for Postoperative Mediastinitis in a Patient With a Left Ventricular Assist Device. Int Heart J. 2015 Sep 29;56(5):574-7. doi: 10.1536/ihj.14-412. Epub 2015 Sep 11. PubMed PMID: 26370363.

11: Kinugawa K, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, Mizuguchi K. Errata: Effectiveness and Adverse Events of Tolvaptan in Octogenarians With Heart Failure. Int Heart J. 2015 Sep 29;56(5):581. doi: 10.1536/ihj.56-5_Errata1. Epub 2015 Sep 4. PubMed PMID: 26346521.

12: Xiong B, Huang Y, Tan J, Yao Y, Wang C, Qian J, Rong S, Deng S, Cao Y, Zou Y, Huang J. The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2015 Nov;20(6):633-42. doi: 10.1007/s10741-015-9503-x. PubMed PMID: 26334632.

13: Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan. Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1749-56. doi: 10.2215/CJN.09941014. Epub 2015 Jul 31. PubMed PMID: 26231191.

14: Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf. 2015 Nov;38(11):1103-13. doi: 10.1007/s40264-015-0327-3. PubMed PMID: 26188764; PubMed Central PMCID: PMC4608984.

15: Tanaka A, Katsuno T, Ozaki T, Sakata F, Kato N, Suzuki Y, Kosugi T, Kato S, Tsuboi N, Sato W, Yasuda Y, Mizuno M, Ito Y, Matsuo S, Maruyama S. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. Acta Cardiol. 2015 Apr;70(2):217-23. PubMed PMID: 26148383.

16: Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol. 2015 Jun 28;7(12):1685-93. doi: 10.4254/wjh.v7.i12.1685. PubMed PMID: 26140088; PubMed Central PMCID: PMC4483550.

17: Horie S. Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease? Kidney Int. 2015 Jul;88(1):14-6. doi: 10.1038/ki.2015.143. PubMed PMID: 26126090.

18: Kogiso T, Tokushige K, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, Torii N, Shiratori K. Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis. Hepatol Res. 2015 Jun 29. doi: 10.1111/hepr.12547. [Epub ahead of print] PubMed PMID: 26123753.

19: Okabe T, Yakushiji T, Igawa W, Ono M, Kido T, Ebara S, Yamashita K, Yamamoto MH, Saito S, Hoshimoto K, Amemiya K, Isomura N, Araki H, Ochiai M. The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study. Cardiovasc Ther. 2015 Oct;33(5):275-81. doi: 10.1111/1755-5922.12142. PubMed PMID: 26122275.

20: Toda H, Nakamura K, Nakahama M, Wada T, Watanabe A, Hashimoto K, Terasaka R, Tokioka K, Nishii N, Miyoshi T, Kohno K, Kawai Y, Miyaji K, Koide Y, Tachibana M, Yoshioka R, Ito H; Tolvaptan Registry Investigators. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size. J Cardiol. 2015 Jun 10. pii: S0914-5087(15)00153-7. doi: 10.1016/j.jjcc.2015.04.017. [Epub ahead of print] PubMed PMID: 26072263.